annb0t
Top 20
TransMedics Group, Inc. TMDX reported fourth-quarter 2024 earnings per share (EPS) of 19 cents, which beat the Zacks Consensus Estimate of 18 cents by 5.6%. The company recorded an EPS of 12 cents in the year-ago period.
TransMedics registered revenues of $121.6 million, up 49.8% year over year. The figure surpassed the Zacks Consensus Estimate by 10.2%. The year-over-year increase in sales was driven by the rise in utilization of the Organ Care System (OCS) across all three organs and addition...
>>> Read more: TransMedics Stock Rises as Q4 Earnings & Revenues Beat Estimates
TransMedics registered revenues of $121.6 million, up 49.8% year over year. The figure surpassed the Zacks Consensus Estimate by 10.2%. The year-over-year increase in sales was driven by the rise in utilization of the Organ Care System (OCS) across all three organs and addition...
>>> Read more: TransMedics Stock Rises as Q4 Earnings & Revenues Beat Estimates
